The Three P’s: Parotid, PD-L1, and Pembrolizumab

We present a case of recurrent, platinum-refractory undifferentiated carcinoma of the parotid which was treated with checkpoint inhibitor, Pembrolizumab, and achieved a complete response to therapy. We review the literature of checkpoint inhibitor use in undifferentiated carcinoma of the parotid.

Bibliographic Details
Published in:	Case Reports in Oncological Medicine
Main Authors:	Amanda Wiggins, Zhaohui Arter, Tamie Kerns
Format:	Article
Language:	English
Published:	Wiley 2019-01-01
Online Access:	http://dx.doi.org/10.1155/2019/2305315

Similar Items

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti–PD-1–refractory Hodgkin lymphoma
by: Philippe Armand, et al.
Published: (2025-10-01)

The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
by: Gagandeep Brar, et al.
Published: (2019-08-01)

Gal-3 blocks the binding between PD-1 and pembrolizumab
by: Henrik Schmidt, et al.
Published: (2024-10-01)

MiR-340-5p regulates PD-L1 and predicts pembrolizumab response in extranodal NK/T-cell lymphoma
by: Kyung Ju Ryu, et al.
Published: (2025-02-01)

pS396/pS404 (PHF1) tau vaccine outperforms pS199/pS202 (AT8) in rTg4510 tauopathy model
by: Jonathan P. Hulse, et al.
Published: (2025-05-01)

The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab
by: Shen Lin, et al.
Published: (2022-04-01)

Pembrolizumab and radiation therapy for multifocal myxofibrosarcoma of the scalp: a case report
by: Christopher Ryan Grant, et al.
Published: (2024-08-01)

Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review
by: Mateusz Kciuk, et al.
Published: (2025-06-01)

Liposarcoma of the Spermatic Cord Masquerading as an Inguinal Hernia
by: William Londeree, et al.
Published: (2014-01-01)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
by: Ning Wan, et al.
Published: (2020-03-01)

Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report
by: Yoichi Nishii, et al.
Published: (2022-07-01)

Novel Mutations in Pilomatrixoma, CTNNB1 p.s45F, and FGFR2 p.s252L: A Report of Three Cases Diagnosed by Fine-Needle Aspiration Biopsy, with Review of the Literature
by: Cristina Aparecida Troques da Silveira Mitteldorf, et al.
Published: (2020-01-01)

89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
by: Annelies Jorritsma-Smit, et al.
Published: (2020-10-01)

PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab
by: Takashi Matsuki, et al.
Published: (2024-08-01)

Lack of Conventional Acinar Cells in Parotid Salivary Gland of Patient Taking an Anti-PD-L1 Immune Checkpoint Inhibitor
by: Sarah Pringle, et al.
Published: (2020-04-01)

PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)
by: Evangelia Pantazaka, et al.
Published: (2022-08-01)

DEVELOPMENT AND VALIDATION OF A METHOD FOR DETERMINING NEUTRALIZING ANTIBODIES TO PEMBROLIZUMAB IN HUMAN SERUM BASED ON INHIBITION OF BINDING OF PEMBROLIZUMAB TO ITS PD-1 TARGET BY ELISA
by: A. M. Kudryashova, et al.
Published: (2019-08-01)

P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA
by: Philippe Armand, et al.
Published: (2023-08-01)

Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab
by: Amanda Enstrom, et al.
Published: (2024-08-01)

Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment
by: Michael Weichenthal, et al.
Published: (2024-12-01)

Pembrolizumab (Keytruda) in blockade of PD-1 Pathway to enhance tumor immunity in Oral squamous cell carcinoma
by: P. Kowsalya
Published: (2024-06-01)

Failure of the PD-1 blocking agent pembrolizumab to benefit a patient with renal squamous cell cancer
by: Salman Khan, et al.
Published: (2024-06-01)

Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland
by: Arjun Bhadhuri, et al.
Published: (2019-12-01)

Quantification of PD-L1 expression and tumor mutational burden in biologically distinct advanced pancreatic cancers responding to pembrolizumab: case reports
by: Kevin Y. Li, et al.
Published: (2024-12-01)

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
by: Lauren Jones, et al.
Published: (2022-11-01)

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
by: Mark Voskoboynik, et al.
Published: (2024-08-01)

Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD‐L1 expression: Updated analysis
by: Yasuyuki Ikezawa, et al.
Published: (2024-07-01)

Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
by: Jeng-Shiuan Tsai, et al.
Published: (2022-11-01)

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1
by: Filippo de Braud, et al.
Published: (2023-06-01)

Severe pemphigus vulgaris and cervical carcinoma treated with anti PD1 antibody pembrolizumab: A therapeutic dilemma?
by: Sophia Wasserer, et al.
Published: (2025-03-01)

Scleroderma Secondary to Pembrolizumab: A Case Report and Review of 19 Cases of Anti-PD-1-Induced Scleroderma
by: Stephanie Farrugia, et al.
Published: (2023-09-01)

742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors
by: David Hong, et al.
Published: (2023-11-01)

Lysine methyltransferase 2D deficiency drives complete response to pembrolizumab in PD-L1-High cholangiocarcinoma: a case report and review of literature
by: Xiaofang Li, et al.
Published: (2025-08-01)

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
by: Rebekah Rittberg, et al.
Published: (2023-05-01)

Correction: PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1
Published: (2024-01-01)

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status
by: Mark Awad, et al.
Published: (2020-10-01)

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
by: Makoto Tahara, et al.
Published: (2022-02-01)

Phase 2 study of first‐line pembrolizumab monotherapy in elderly patients with non‐small‐cell lung cancer expressing high PD‐L1
by: Takeshi Masuda, et al.
Published: (2022-06-01)

Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
by: Alessio Cirillo, et al.
Published: (2024-04-01)

Dynamic monitoring of PD‐L1 and Ki67 in circulating tumor cells of metastatic non‐small cell lung cancer patients treated with pembrolizumab
by: Maria Spiliotaki, et al.
Published: (2023-05-01)